BECAIT Trial
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To evaluate if bezafibrate could slow the progression of coronary stenoses in dyslipidemic male survivors of myocardial infarction who were younger than 45 years at the time of the event.
Method
The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) was a randomized, double-blinded, placebo-controlled trial over 5 years to assess the angiographic benefits of bezafibrate retard (400 mg a day) in 92 young (45 yrs), male, post-myocardial infarction (post-MI) patients with dyslipidemia (fasting serum cholesterol concentration above 240 mg/dL and triglyceride concentration above 141 mg/dL).
Results
- Bezafibrate reduced the levels of LDL-C and triglycerides by 53% and 46% respectively
- Plasma apolipoprotein (apo) B levels reduced by 9%
- HDL3 levels rose by 9%
Conclusion
The effect of bezafibrate on progression of focal coronary atherosclerosis could be at least partly attributed to a rise in HDL3 cholesterol and a decrease in the total number of apo B-containing lipoproteins. Treatment with bezafibrate also significantly reduced the levels of insulin-like growth factor (IGF-1) which is one other factor associated with disease progression.[1][2][3][4]
References
- ↑ Ruotolo G, Ericsson CG, Tettamanti C; et al. (1998). “Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)”. J. Am. Coll. Cardiol. 32 (6): 1648–56. PMID 9822092. Unknown parameter
|month=ignored (help) - ↑ de Faire U, Ericsson CG, Hamsten A, Nilsson J (1995). “Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)”. Drugs Exp Clin Res. 21 (3): 105–24. PMID 7555614.
- ↑ Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U (1996). “Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients”. Lancet. 347 (9005): 849–53. PMID 8622389. Unknown parameter
|month=ignored (help) - ↑ Ericsson CG (1998). “Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress”. Eur. Heart J. 19 Suppl H: H37–41. PMID 9717064. Unknown parameter
|month=ignored (help)
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH